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Abstract The L-adrenergic agonist isoproterenol increased the
phosphorylation of elongation factor eEF2 in ventricular
cardiomyocytes from adult rats (ARVC). Phosphorylation of
eEF2 inhibits its activity, and protein synthesis was inhibited in
ARVC concomitantly with increased eEF2 phosphorylation.
eEF2 kinase activity in ARVC extracts was completely
dependent upon Ca2+/calmodulin. In contrast to other cell types,
however, treatments designed to raise intracellular cAMP failed
to induce Ca2+/calmodulin-independent activity. Instead, they
increased maximal eEF2 kinase activity. Similar data were
obtained when partially purified ARVC eEF2 kinase was treated
with cAMP-dependent protein kinase in vitro. These data
suggest that ARVC possess a distinct isoform of eEF2
kinase. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
A number of agents and conditions modulate the rate of
mRNA translation in isolated cardiac myocytes from adult
animals. These include insulin (and related growth factors)
and K-adrenergic agonists, such as phenylephrine, which acti-
vate protein synthesis acutely [1^6]. This is connected with the
general anabolic e¡ect of insulin and the ability of the latter
two agents to promote hypertrophy of cardiac tissue. Con-
versely, L-adrenergic stimulation results in inhibition of pro-
tein synthesis [7]. Such agonists exert inotropic and chrono-
tropic e¡ects on cardiac contraction, a process which, like
protein synthesis, consumes ATP. It is therefore physiologi-
cally reasonable that in parallel with promoting contraction,
such treatment would also switch o¡ processes such as protein
synthesis, which compete with it for the available ATP. How-
ever, the mechanisms underlying the ability of L-agonists to
inhibit cardiac protein synthesis remain obscure. Since one of
the main actions of these agents is to raise cellular cAMP
levels, it seems likely that cAMP may act to inhibit a compo-
nent or components of the translational machinery.
Although a good deal of e¡ort has been devoted to under-
standing the molecular mechanisms involved in regulating
mRNA translation in animal cells, little attention has been
directed to exploring possible links to cAMP. One possible
link is the phosphorylation of elongation factor 2, eEF2,
which inhibits the activity of this protein. eEF2 is phosphor-
ylated at Thr56 by a protein kinase termed eEF2 kinase (re-
viewed in [8]), which is a member of a recently discovered and
novel group of protein kinases [9]. eEF2 kinase is normally
dependent on Ca ions and calmodulin (Ca/CaM) for activity
[8,10,11]. An early study showed that eEF2 kinase was a sub-
strate for cAMP-dependent protein kinase (PKA) in vitro and
that this led to activation of eEF2 kinase, by rendering it less
dependent on Ca/CaM for activity [12]. This therefore pro-
vided a potential mechanism for the regulation of elongation
by agonists which raise cAMP. Consistent with this, two sub-
sequent studies, in adipocytes [13] and myeloid cells [14], have
shown that treatment of cells with agents which activate PKA
leads to increased phosphorylation of eEF2 and inhibition of
peptide-chain elongation.
Here we show that L-adrenergic agonists increase eEF2
phosphorylation in isolated ventricular cardiomyocytes and
that this correlates with inhibition of protein synthesis. Sur-
prisingly, these treatments do not alter the requirement of
cardiac eEF2 kinase for Ca/CaM but instead increase its max-
imal activity.
2. Materials and methods
2.1. Chemicals and biochemicals
These items were obtained as described earlier or were purchased
from Sigma (Poole, Dorset).
2.2. Isolation, culture and extraction of cardiac myocytes
Cardiomyocytes (ARVC, adult rat ventricular myocytes) were pre-
pared and maintained in culture overnight (unless otherwise stated) as
described earlier [3].
2.3. Gel electrophoresis and immunoblotting
These techniques were performed as described earlier [3]. The anti-
(P)eEF2 antibody was prepared using the peptide described by Marin
et al. [15] and puri¢ed by chromatography successively on columns to
which the phospho and dephospho forms of the peptide had been
immobilised. The ¢nal preparation of anti-(P)eEF2 antibody did not
recognise non-phosphorylated eEF2.
2.4. Assays for eEF2 kinase activity
eEF2 kinase assays were performed using 15^20 Wg cell protein per
assay in the presence and absence of calcium ions and calmodulin, as
described earlier [16,17] using puri¢ed eEF2 (0.3 Wg/assay) as sub-
strate. Assays were performed for 20 min at 30‡C and reactions
were stopped with the addition of 5USDS sample bu¡er. Samples
were analysed on 10% SDS^PAGE. The gels were Coomassie stained,
destained, dried and then exposed to X-ray ¢lm (Konica).
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 1 0 0 - 7
*Corresponding author. Fax: (44)-1382-322424.
E-mail: c.g.proud@dundee.ac.uk
FEBS 24551 25-1-01
FEBS 24551 FEBS Letters 489 (2001) 225^228
2.5. Measurement of protein synthesis
Cells were isolated and treated as before. Cells were incubated with
methionine-free MEM for 2 h to reduce background incorporation of
methionine into synthesised proteins. The experiment was performed
in triplicate. [35S]methionine (15^20 WCi/ml) was added to control cells
for 15 min. Isoproterenol was added to experimental cells for desig-
nated times (2, 5 or 10 min) before the addition of [35S]methionine for
15 min. Cells were lysed and protein extracted as before. Protein
content was quanti¢ed and three equal amounts of each lysate were
spotted onto squares of 3 mm ¢lter paper. The paper was boiled twice
for 2 min in 5% TCA with 0.5 mM cold methionine. The papers were
washed in cold 5% TCA and then in ethanol and dried.
[35S]methionine incorporation was measured by scintillation counting.
2.6. Partial puri¢cation of eEF2 kinase
eEF2 kinase was puri¢ed from extracts of control or isoproterenol-
treated heart cells by ion-exchange chromatography on Mono-Q using
an Aº kta FPLC system (Pharmacia). The column was washed with low
salt bu¡er (0.1 M KCl in 20 mM HEPES^KOH, pH 7.5; 0.1 mM
EDTA; 15 mM L-mercaptoethanol) before the samples were applied.
The column was developed with an increasing gradient of salt up to
0.5 M KCl in the same bu¡er. Fractions were collected and assayed as
before for eEF2 kinase activity.
3. Results
3.1. Isoproterenol elicits phosphorylation of eEF2 in ARVC
via the L-adrenergic receptor
Isoproterenol is a potent L-adrenergic agonist that increases
cAMP levels in the heart. In ARVC it brought about a rapid
increase in phosphorylation of eEF2 as analysed using an
anti-serum that speci¢cally recognises eEF2 when it is phos-
phorylated as the main site of phosphorylation, Thr56. In 10
separate experiments, isoproterenol increased the phosphory-
lation state of eEF2 (Fig. 1A), the increase being evident as
early as 1 min after treatment of the cells with isoproterenol.
The level of eEF2 phosphorylation remained elevated for at
least 20 min after isoproterenol stimulation. We have previ-
ously shown that insulin decreases the level of eEF2 phos-
phorylation in ARVC [3] (see also Fig. 1A). It was therefore
of interest to study whether isoproterenol still increased eEF2
phosphorylation in cells pretreated with insulin. Addition of
isoproterenol to insulin-treated ARVC led to a substantial rise
in eEF2 phosphorylation which increased almost to the levels
observed in cells which had not been pretreated with insulin,
i.e. more markedly than in control cells where there is signi¢-
cant basal phosphorylation of eEF2. Thus, the e¡ect of iso-
proterenol is clearly dominant over the e¡ect of insulin.
To verify that the e¡ects of isoproterenol were mediated
through the L-adrenoreceptor, we employed the L-speci¢c an-
tagonist, propranolol. This compound completely blocked the
ability of isoproterenol to induce phosphorylation of eEF2 in
control or insulin-pretreated AVRC (Fig. 1B).
3.2. Arti¢cially elevating cAMP increases eEF2
phosphorylation in ARVC
Since isoproterenol increases cAMP levels by activating ad-
enyl cyclase, it was likely that e¡ect of isoproterenol upon the
phosphorylation of eEF2 was mediated by cAMP. To inves-
tigate this, we employed strategies designed to increase the
intracellular cAMP level in ARVC. Treatment of ARVC
with the cAMP analogue chlorophenylthio-cAMP (CPT-
cAMP) also induced the phosphorylation of eEF2, albeit
over a somewhat longer time-scale than isoproterenol (Fig.
1C). This indicates that arti¢cial increases in cAMP can cause
Fig. 1. E¡ect of insulin and isoproterenol on eEF2 phosphorylation
in ARVC. Panel A: ARVC were cultured overnight and, in some
cases (where shown) were then treated with insulin (Ins, 10 nM) for
20 min. Where indicated, isoproterenol (Iso, 1 WM) was added to
the times shown. Cells were extracted and samples were applied to
SDS^PA gels and subjected to immunoblotting with anti-phospho
eEF2 antibody (upper blot) and, as a loading control, an anti-eEF2
antibody which does not distinguish the phosphorylated protein
(lower blot). Panel B: Overnight cultures of ARVC were treated
with insulin and isoproterenol, as for panel A. In some cases, cells
were incubated with 20 WM propranolol (prop) for 20 min prior to
the addition of isoproterenol. The blots were probed with an anti-
phospho eEF2 antibody. Loading controls (as in panel A) estab-
lished equal loading of samples in each lane (data not shown). Panel
C: Overnight cultures of ARVC were treated with 0.5 mM CPT-
cAMP or 1 WM forskolin for the times indicated (min). The blot
was probed with an anti-phospho eEF2 antibody. Loading controls
(as in panel A) established equal loading of samples in each lane
(data not shown).
Fig. 2. E¡ect of isoproterenol on the rate of protein synthesis in
ARVC. Overnight cultures of ARVC were incubated for 2 h in me-
thionine-free medium before addition of isoproterenol for the speci-
¢ed times. The times indicate the end of the 15 min incubation with
[35S]methionine. Cells were extracted at this time point, and the pro-
tein concentration of each extract was assayed. The incorporated ra-
dioactivity was counted in a scintillation counter, and corrected for
the protein concentration of the extract. Assays were performed in
triplicate plates for each condition, and each plate was assayed in
duplicate. The data shown are representatives of two further experi-
ments performed.
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this e¡ect. As an alternative way to increase intracellular
cAMP concentrations, we treated ARVC with forskolin,
which activates adenyl cyclase. This results in increased phos-
phorylation of eEF2 (Fig. 1C), to a greater extent than CPT-
cAMP. Taken together, these data strongly suggest that the
e¡ect of isoproterenol is mediated through cAMP rather than
any other possible downstream consequence of activating
L-adrenoreceptors.
3.3. Increased phosphorylation of eEF2 correlates with
inhibition of protein synthesis in ARVC
To study whether the treatment of cells with isoproterenol
a¡ected the rate of protein synthesis, we measured the incor-
poration of [35S]methionine into newly synthesised protein in
ARVC. Treatment with isoproterenol markedly reduced the
protein synthesis as compared to untreated controls (Fig. 2).
Thus, the isoproterenol-induced increase in eEF2 phosphory-
lation is associated with inhibition of overall protein synthesis,
consistent with the fact that phosphorylation of eEF2 inacti-
vates it. The standard procedures to assess whether elongation
is indeed inhibited ^ i.e. transit time measurements or poly-
some pro¢les ^ could not be carried out using ARVC due to
the very small amounts of radiolabel incorporated and/or in-
su⁄cient quantities of isolated cells available.
3.4. Isoproterenol and CPT-cAMP cause activation of
eEF2 kinase in ARVC but do not increase its
Ca/CaM-independent activity
In the case of eEF2 kinase from rabbit reticulocytes, phos-
phorylation by PKA increased its Ca/CaM-independent activ-
ity without increasing its activity measured in the presence of
Ca/CaM [12]. Similarly, in both adipocytes and myeloid cells
[13,14], treatments designed to increase intracellular cAMP
led to a marked rise in the Ca/CaM-independent activity with-
out discernibly altering the maximal activity of the kinase. In
contrast, when eEF2 kinase activity was measured in extracts
from ARVC treated with isoproterenol or CPT-cAMP, no
Ca-independent activity was evident, as was also the case
for untreated cells (Fig. 3).
3.5. Characteristics of eEF2 kinase in ARVC
It was clearly possible that isoproterenol activated a second
isoform of eEF2 kinase which is distinct from the form(s) so
far found in other tissues. To examine whether ARVC express
more than one isoform of eEF2 kinase, extracts from control
or isoproterenol-treated ARVC were fractionated by FPLC
on Mono-Q and fractions were assayed for their ability to
phosphorylate eEF2. All the eEF2 kinase activity was retained
on the column, which was then developed with a gradient of
KCl up to 0.5 M. Only a single symmetrical peak of eEF2
kinase activity was observed in either case (Fig. 4A). The
elution position of this peak is similar (in terms of ionic
strength) to that of eEF2 kinase from other sources (e.g. re-
ticulocyte lysates [18]). This indicates that it is unlikely that
isoproterenol activates an additional form of eEF2 kinase or
an alternative kinase that phosphorylates eEF2.
The peak fractions from the Mono-Q column from control
cells were pretreated with PKA prior to assay for eEF2 kinase
activity to examine whether, as for eEF2 kinase from other
sources, this manipulation increased the Ca-independent ac-
tivity of eEF2k. PKA treatment clearly markedly increased
the maximal activity of cardiac eEF2 kinase (measured in
the presence of Ca ions) but had no e¡ect upon the Ca-in-
dependent activity (Fig. 4B). Thus, PKA does not elicit Ca-
independent activity for eEF2 kinase from ARVC.
4. Discussion
The data presented here show for the ¢rst time that L-ad-
renergic stimulation leads to the phosphorylation of eEF2 in
cardiomyocytes, an e¡ect which is known to cause inactiva-
tion of eEF2. The phosphorylation of eEF2 correlates with
inhibition of overall protein synthesis induced by L-adrenergic
stimulation of the cells and it is likely that the inhibitory e¡ect
of L-adrenergic stimulation on protein synthesis is due (at
least in part) to the increased phosphorylation of eEF2. Inhi-
bition of protein synthesis under this condition will reduce the
Fig. 3. E¡ect of isoproterenol or CPT-cAMP on eEF2K activity in
ARVC. ARVC which had been cultured overnight were treated
with 1 WM isoproterenol (Iso) or 0.5 mM CPT-cAMP (CPT) for the
times indicated (in min). Extracts were prepared and assayed for
eEF2K activity in the presence or absence of Ca2/CaM (as indi-
cated). The intensity of the signals for the assays performed in the
presence of Ca2/CaM was assessed by phosphorimage analysis
(Fuji). The strength of each signal is expressed as a percentage of
the control (numbers below each lane).
Fig. 4. Characteristics of eEF2K activity in ARVC. Panel A:
ARVC which had been cultured overnight were treated for 5 min
with isoproterenol (1 WM). The cell lysate was applied to a Mono-Q
column which was developed with a gradient of KCl and fractions
were collected. The fractions were assayed for eEF2K activity in the
presence of Ca/CaM, along with the load (lysate) and the £ow-
through from the column. Certain fractions were pooled prior to as-
say, as indicated. Panel B: Freshly isolated ARVC were extracted
and applied to a Mono-Q column which was developed with a gra-
dient of KCl. Fractions were collected. Those containing the eEF2K
activity were preincubated with cold ATP/Mg with or without PKA
(as indicated, 20 mU in 20 Wl total volume) for 20 min in the ab-
sence of Ca2/CaM. The fractions were assayed for eEF2 kinase ac-
tivity using [Q-32P]ATP in the presence or absence of Ca2/CaM, as
indicated. Fraction numbers di¡er from those in panel A due to dif-
ferences in the FPLC programme used, but peak eEF2 kinase activ-
ity eluted in the same position (KCl concentration) as in panel A.
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consumption of ATP making more metabolic energy available
to support cardiac contraction, which is activated by L-adren-
ergic agonists. Earlier work showed that glucagon inhibits
protein synthesis in liver cells and that this involved reduced
rates of peptide-chain elongation [19,20]. Similarly, the recent
study of Diggle et al. [13] showed that L-adrenergic stimula-
tion of adipocytes led to inhibition of both protein synthesis
and rates of elongation. Thus, inhibition of elongation may be
a general response to elevation of cAMP in mammalian cells,
as a mechanism to divert either metabolic energy or metabolic
precursors (e.g. amino acids in liver) away from protein syn-
thesis and into other processes (contraction in heart or gluco-
neogenesis in liver). Elongation represents a more suitable
point of inhibition here, since polysomes remain intact and
translation could quickly be resumed once the requirement for
energy or fuel has passed. Inhibition of initiation would, on
the other hand, cause disaggregation of polysomes with likely
di¡erential e¡ects upon the translation of di¡erent transcripts.
A striking di¡erence between the ¢ndings of this study and
those of earlier investigators is that here elevating cAMP does
not alter the basal, Ca-independent, activity of eEF2k but
rather increases its maximal activity measured in the presence
of Ca/CaM. This e¡ect was consistently observed in extracts
of intact cells treated with L-adrenergic agonist, following
treatment of cell extracts with puri¢ed PKA and when the
partially puri¢ed eEF2 kinase from ARVC was treated with
PKA. One plausible explanation for this di¡erence from other
cell types previously examined (reticulocytes, 3T3-L1 adipo-
cytes, primary adipocytes, IPC-81 myeloid cells) is that ven-
tricular myocytes express a di¡erent isoform of eEF2 kinase
which has di¡erent regulatory properties. It could well be
physiologically important that heart cells do not rely on
changes in the Ca-sensitivity of eEF2 kinase in order to reg-
ulate elongation, since Ca levels £uctuate on a beat-to-beat
basis in these cells, unlike many other cell types where they
are only raised acutely in response to growth factors, hor-
mones or other stimuli. Altering the maximal activity of
eEF2 kinase would thus o¡er a more rational basis for a¡ect-
ing eEF2 phosphorylation in ARVC.
The idea that di¡erent cell types may possess di¡erent
forms of eEF2 kinase is not entirely new, although this report
provides the ¢rst indication that di¡erent isoforms may have
distinct regulatory properties. Hait et al. [21] have previously
provided immunological evidence that certain tissues express
distinct forms of eEF2 kinase. For example, an antibody
raised to eEF2 kinase failed to detect a protein of the expected
size in several tissues (heart was not analysed) which possess
high levels of eEF2 kinase activity. In this context, it is nota-
ble that we were unable to obtain any signal for eEF2 kinase
on Western blots for the peak fractions from the FPLC puri-
¢cation experiments described here using any of three di¡er-
ent antisera to eEF2 kinase from other tissues. These were
raised either to the whole eEF2 kinase protein (expressed in
Escherichia coli using the muscle cDNA described in [22]) or
two peptides who were based on parts of the translated amino
acid sequence of this cDNA. This observation is consistent
with the existence in cardiomyocytes of a distinct isoform of
eEF2 kinase, although further work will be required to clarify
this.
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